CytoDyn’s Monotherapy Trial with Leronlimab (PRO 140) Reaches its Ultimate Goals

World News: . []

VANCOUVER Washington May 06 2019 GLOBE NEWSWIRE -- LINK  Inc OTCQB CYDY CytoDyn or the Company a late stage biotechnology company developing leronlimab PRO 140 a CCR5 antagonist with the LINK  for multiple therape utic in...

More news and information about CytoDyn Inc.

Published By:

Globe Newswire: 11:00 GMT Monday 6th May 2019

Published: .

Search for other references to "cytodyn" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us